| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of CytomX Therapeutics (NASDAQ:CTMX) through any online brokerage.
Other companies in CytomX Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
CytomX Therapeutics has a consensus price target of $10.60.
The stock price for CytomX Therapeutics (NASDAQ: CTMX) is $2.2501 last updated October 15, 2026 at 4:51 AM EDT.
There are no upcoming dividends for CytomX Therapeutics.
CytomX Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for CytomX Therapeutics.
CytomX Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
